Safety profile of Pertuzumab with Trastuzumab and Docetaxel in patients from Asia with human epidermal growth factor receptor 2-positive metastatic breast cancer: results from the phase III trial CLEOPATRA.

Cardiotoxicity of anticancer treatments. Nat Rev Cardiol (2015) 2.28

Recent advances in the development of anti-HER2 antibodies and antibody-drug conjugates. Ann Transl Med (2014) 0.86

Breast Cancer: Conventional Diagnosis and Treatment Modalities and Recent Patents and Technologies. Breast Cancer (Auckl) (2015) 0.83

Taxane acute pain syndrome (TAPS) in patients receiving taxane-based chemotherapy for breast cancer-a systematic review. Support Care Cancer (2016) 0.80

Pertuzumab for the treatment of patients with human epidermal growth factor receptor 2-positive breast cancer in Japan. Mol Clin Oncol (2015) 0.75

Outcomes of re-treatment with first-line trastuzumab plus a taxane in HER2 positive metastatic breast cancer patients after (neo)adjuvant trastuzumab: A prospective multicenter study. Oncotarget (2016) 0.75

Feasibility and Efficacy of Eribulin Mesilate in Korean Patients with Metastatic Breast Cancer: Korean Multi-center Phase IV Clinical Study Results. Cancer Res Treat (2016) 0.75

Trastuzumab-Docetaxel Combination Chemotherapy Induced Severe Onychopathy. Indian Dermatol Online J (2017) 0.75

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med (2001) 44.67

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med (2005) 33.60

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med (2005) 28.25

Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med (2006) 17.08

Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med (2011) 12.52

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med (2011) 12.45

2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol (2006) 11.26

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol (2005) 8.87

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med (2007) 8.02

Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature (2003) 6.78

Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell (2004) 6.12

The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist (2009) 6.00

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol (2013) 3.87

Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev (2002) 3.73

Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Res (2009) 2.68

Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol (1998) 2.52

Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study. J Clin Oncol (2010) 2.35

The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance. Clin Cancer Res (2000) 2.14

Adequacy of published oncology randomized controlled trials to provide therapeutic details needed for clinical application. J Natl Cancer Inst (2010) 2.09

Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet (2010) 2.08

Noninvasive tests of CYP3A enzymes. Pharmacogenetics (1994) 1.69

Optimizing the erythromycin breath test for use in cancer patients. Clin Cancer Res (2000) 1.60

Randomized pharmacokinetic and pharmacodynamic study of docetaxel: dosing based on body-surface area compared with individualized dosing based on cytochrome P450 activity estimated using a urinary metabolite of exogenous cortisol. J Clin Oncol (2005) 1.50

Role of human cytochrome P450 3A4 and 3A5 in the metabolism of taxotere and its derivatives: enzyme specificity, interindividual distribution and metabolic contribution in human liver. Pharmacogenetics (1998) 1.38

Pharmacokinetics and toxicity of docetaxel: role of CYP3A, MDR1, and GST polymorphisms. Clin Pharmacol Ther (2006) 1.38

Use of midazolam as a human cytochrome P450 3A probe: I. In vitro-in vivo correlations in liver transplant patients. J Pharmacol Exp Ther (1994) 1.36

Body surface area as a determinant of pharmacokinetics and drug dosing. Invest New Drugs (2001) 1.35

Population distribution and effects on drug metabolism of a genetic variant in the 5' promoter region of CYP3A4. Clin Pharmacol Ther (1999) 1.34

Common allelic variants of cytochrome P4503A4 and their prevalence in different populations. Pharmacogenetics (2002) 1.30

Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies. J Clin Oncol (2002) 1.26

Use of midazolam as a human cytochrome P450 3A probe: II. Characterization of inter- and intraindividual hepatic CYP3A variability after liver transplantation. J Pharmacol Exp Ther (1994) 1.22

Acute toxicity of adjuvant doxorubicin and cyclophosphamide for early breast cancer -- a retrospective review of Chinese patients and comparison with an historic Western series. Radiother Oncol (2002) 1.02

Dexamethasone as a probe for docetaxel clearance. Cancer Chemother Pharmacol (2004) 1.02

Comparison of urinary 6-beta-cortisol and the erythromycin breath test as measures of hepatic P450IIIA (CYP3A) activity. Clin Pharmacol Ther (1992) 1.00

CYP450 pharmacogenetics for personalizing cancer therapy. Drug Resist Updat (2008) 0.99

Correlation between docetaxel clearance and estimated cytochrome P450 activity by urinary metabolite of exogenous cortisol. J Clin Oncol (2000) 0.97

The erythromycin breath test for the prediction of drug clearance. Clin Pharmacokinet (2001) 0.96

Metabolism of docetaxel by human cytochromes P450: interactions with paclitaxel and other antineoplastic drugs. Cancer Res (1996) 0.95

Racial differences in acute toxicities of neoadjuvant or adjuvant chemotherapy in patients with early-stage breast cancer. Eur J Cancer (2011) 0.95

The influence of dose and ethnic origins on the pharmacokinetics of nifedipine. Clin Pharmacol Ther (1993) 0.93

Accuracy and clinical utility of simplified tests of antipyrine metabolism. Br J Clin Pharmacol (1984) 0.86

Polymorphism of cytochrome P-450 in humans. Trends Pharmacol Sci (1989) 0.85

Differences in the urinary excretion of 6-beta-hydroxycortisol/cortisol between Asian and Caucasian women. J Clin Pharmacol (1999) 0.83

CYP3A4*16 and CYP3A4*18 alleles found in East Asians exhibit differential catalytic activities for seven CYP3A4 substrate drugs. Drug Metab Dispos (2010) 0.82

Absence of pharmacokinetic drug-drug interaction of pertuzumab with trastuzumab and docetaxel. Anticancer Drugs (2013) 0.81

Dose optimisation of carboplatin in adults. Anticancer Res (1995) 0.80